Eli Lilly and Company
General ticker "LLY" information:
- Sector: Health Care
- Industry: Drug Manufacturers - General
- Capitalization: $786.8B (TTM average)
Eli Lilly and Company follows the US Stock Market performance with the rate: 42.9%.
Estimated limits based on current volatility of 2.2%: low 1065.42$, high 1112.24$
Factors to consider:
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2026-05-15, amount 1.73$ (Y0.64%)
- Total employees count: 47000 (+9.3%) as of 2024
- US accounted for 19.9% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: R&D failure, Regulatory and compliance, Pricing pressure, IP loss, Supply chain disruptions
- Price in estimated range
- Earnings for 3 months up through Q1 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [766.78$, 1093.84$]
- 2026-12-31 to 2027-12-31 estimated range: [835.20$, 1176.99$]
Financial Metrics affecting the LLY estimates:
- Negative: with PPE of 44.2 at the end of fiscal year the price was high
- Positive: Operating profit margin, % of 40.35 > 18.39
- Positive: -0.02 < Operating cash flow per share per price, % of 1.75
- Positive: -4.41 < Investing cash flow per share per price, % of -1.14
- Positive: Industry earnings per price (median), % of 5.49 > 4.45
- Positive: Return on assets ratio (scaled to [-100,100]) of 15.51 > 6.06
- Positive: 5.46 < Industry operating cash flow per share per price (median), % of 5.61
Short-term LLY quotes
Relationship graph
Long-term LLY plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $34,124.00MM | $45,043.00MM | $65,179.00MM |
| Operating Expenses | $27,667.00MM | $32,144.00MM | $38,877.00MM |
| Operating Income | $6,457.00MM | $12,899.00MM | $26,302.00MM |
| Non-Operating Income | $97.00MM | $-219.00MM | $-571.00MM |
| R&D Expense | $9,313.00MM | $10,991.00MM | $13,337.00MM |
| Income(Loss) | $6,554.00MM | $12,680.00MM | $25,731.00MM |
| Taxes | $1,314.00MM | $2,090.00MM | $5,091.00MM |
| Net Income(Loss)* | $5,240.40MM | $10,590.00MM | $20,638.30MM |
| Stockholders Equity | $10,771.90MM | $14,192.10MM | $26,535.00MM |
| Inventory | $5,772.80MM | $7,589.20MM | $13,744.00MM |
| Assets | $64,006.30MM | $78,714.90MM | $112,476.00MM |
| Operating Cash Flow | $4,240.00MM | $8,818.00MM | $16,813.00MM |
| Capital expenditure | $7,392.10MM | $8,403.60MM | $7,841.00MM |
| Investing Cash Flow | $-7,153.00MM | $-9,302.00MM | $-10,972.00MM |
| Financing Cash Flow | $3,496.00MM | $1,230.00MM | $-2,213.00MM |
| Earnings Per Share** | $5.83 | $11.76 | $22.98 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.